The US Food and Drug Administration has approved Merck’s second anti-viral drug Molnupiravir, revealed sources.
The report stated that the prescription capsule, which will be taken at house, is designed to cease the development of COVID-19 from gentle to extreme signs in individuals at excessive danger.
‘Molnupiravir should be given within five days of COVID-19 symptoms beginning and should only be given to adults because it may affect bone and cartilage growth, the FDA noted. The drug is not recommended for use during pregnancy because animal studies suggest it may damage the fetus.’
In knowledge introduced to an FDA advisory panel in late November, the drug was proven to stop 30 per cent of infections from progressing – far fewer than Pfizer’s antiviral Paxlovid, which the FDA approved on Wednesday, the report added.
Several docs instructed USA Today that they’d solely prescribe molnupiravir if they’d no different various, and the FDA appeared to echo that by noting in its authorisation announcement that the drug is for use by individuals at excessive danger for extreme illness “for whom alternative Covid-19 treatment options authorised by the FDA are not accessible or clinically appropriate”.